Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3454738 in Adults With Chronic Spontaneous Urticaria
NCT04159701Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of ucenprubart in chronic spontaneous urticaria (CSU), sponsored by Eli Lilly and Company. Started Nov 2019; status: terminated.
02
Drugs
ucenprubart
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04159701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159701.